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Abstract
The protein clusterin has been implicated in the molecular alterations that occur in
articular cartilage during osteoarthritis (OA). Clusterin exists in two isoforms with op-
posing functions, and their roles in cartilage have not been explored. The secreted form
of clusterin (sCLU) is a cytoprotective extracellular chaperone that prevents protein
aggregation, enhances cell proliferation and promotes viability, whereas nuclear clus-
terin acts as a pro‐death signal. Therefore, these two clusterin isoforms may be putative
molecular markers of repair and catabolic responses in cartilage and the ratio between
them may be important. In this study, we focused on sCLU and used established,
pathophysiologically relevant, in vitro models to understand its role in cytokine‐
stimulated cartilage degradation. The secretome of equine cartilage explants, os-
teochondral biopsies and isolated unpassaged chondrocytes was analyzed by western
blotting for released sCLU, cartilage oligomeric protein (COMP) and matrix metallo-
proteinases (MMP) 3 and 13, following treatment with the proinflammatory cytokines
interleukin‐1β (IL‐1β) and tumor necrosis factor‐α. Release of sulfated glycosami-
noglycans (sGAG) was determined using the dimethylmethylene blue assay. Clusterin
messenger RNA (mRNA) expression was quantified by quantitative real‐time poly-
merase chain reaction. MMP‐3, MMP‐13, COMP, and sGAG release from explants and
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osteochondral biopsies was elevated with cytokine treatment, confirming cartilage
degradation in these models. sCLU release was attenuated with cytokine treatment in
all models, potentially limiting its cytoprotective function. Clusterin mRNA expression
was down‐regulated 7‐days post cytokine stimulation. These observations implicate
sCLU in catabolic responses of chondrocytes, but further studies are required to
evaluate its role in OA and its potential as an investigative biomarker.
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1 | INTRODUCTION
Osteoarthritis (OA), the leading cause of physical disability in adults,
is a degenerative disease of synovial joints characterized by low‐
grade inflammation, subchondral bone remodeling, and progressive
degradation and loss of articular cartilage.1 There is an acute need
for robust biomarkers which can identify the onset of the disease
during the earliest stages, enable monitoring of progression, and
assess efficacy of emerging therapeutic interventions in clinical trials.
Identification of molecular alterations that can serve as early markers
of degenerative changes in OA is paramount. This is especially im-
portant since early degenerative changes in the joint can be
asymptomatic for years, and patients often show clinical signs once
joint damage is extensive and cartilage loss may be irreversible.2
Newly synthesized molecules secreted by chondrocytes in early
stages of the disease, along with breakdown products of cartilage
extracellular matrix (ECM), are potential biochemical markers of
early degenerative changes in OA. To date, ECM degradation pro-
ducts have not yet yielded clinically robust biomarkers of early OA.3
Neo‐epitopes of type II collagen breakdown serve as excellent mar-
kers of cartilage degradation, but only in later stages of the disease.
In our laboratory we have focused our efforts on identifying secreted
molecules in the secretome of cartilage, which may be indicators of
cellular and molecular alterations in the early stages of OA.
We have previously used proteomics to identify clusterin (CLU)
in the secretome of an equine explant model of cartilage degrada-
tion.4 CLU, also known as apolipoprotein J, is a secreted glycoprotein
constitutively expressed in a broad spectrum of tissues, and has been
functionally implicated in numerous physiological processes and age‐
related diseases, including OA.5 CLU exists in two isoforms, a gly-
cosylated secretory form (secreted form of clusterin [sCLU]) and a
non‐glycosylated cytoplasmic form, which can translocate to the
nucleus under stress conditions and initiate apoptosis (nuclear clus-
terin [nCLU]),6‐8 although some of the published studies did not
confirm nuclear localization of clusterin isoforms.7 sCLU has cyto-
protective functions and binds to numerous proteins preventing their
aggregation, and initiating disposal by phagocytic cells.9‐12
CLU was identified in the secretome of human healthy and OA
cartilage explants as an endogenous protein released at significantly
lower amounts from hip OA samples.13 Lower levels of CLU were
found to be associated with greater cartilage lesion size.14 We are
particularly interested in the biology of this protein and clinical po-
tential of sCLU as an exploratory biomarker in OA, due to its presence
in serum and synovial fluid.15 Alterations in CLU expression have
previously been described in OA cartilage and synovial fluid.4,15‐23
However, these studies have reported contrasting results, with both
increases and decreases in CLU expression. We believe this is due to
the existence of the two CLU isoforms, with opposing biological
functions, which have not previously been distinguished in OA.
In this study, we focused exclusively on the expression and secretion
of sCLU in models of in vitro cartilage degradation through targeted
biochemical analysis. We utilized cartilage explants, osteochondral biop-
sies and primary chondrocyte model systems to determine sCLU secre-
tion with and without addition of the proinflammatory cytokines
interleukin‐1β (IL‐1β) and tumor necrosis factor‐α (TNF‐α). We also
used IL‐1β and TNF‐α in combination with dexamethasone, a steroidal
anti‐inflammatory drug commonly used to treat joint inflammation,24,25
to ascertain the potential of sCLU to monitor anti‐inflammatory drug
efficacy. Cartilage degradation in these models was determined by the
quantification of known catabolic markers matrix metalloproteinases
(MMP) 3 and 13, loss of cartilage oligomeric protein (COMP) and release
of sulfated glycosaminoglycan (sGAG).4 Our aim was to validate sCLU, a
protein previously implicated in OA pathophysiology, as a putative bio-
marker of early degenerative changes induced by proinflammatory cy-
tokines implicated in low‐grade inflammation in OA using three in vitro
culture model systems.
2 | METHODS
2.1 | Chemicals and reagents
All reagents were supplied by Sigma‐Aldrich UK unless otherwise
stated.
2.1.1 | Cartilage and osteochondral explant culture
Macroscopically normal equine articular cartilage was obtained from
the weight bearing region of the metacarpophalangeal joint of nine
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horses. Animals were sourced from an abattoir and euthanized for
purposes other than research. The study received the full approval of
the local ethics committee and was exempt from review by animal
welfare authorities as abattoir tissue was used.
Six‐millimeter diameter explants of cartilage of equal thickness
were harvested aseptically using a sterile biopsy punch (Steifel), and
10 mm osteochondral explants were isolated using an osteochon-
dral autograft transfer system (Arthrex). Explants were placed into
low glucose (1 g/L) Dulbecco's modified Eagle's medium (DMEM)
supplemented with 200 mM glutamine, 500 µg/mL penicillin,
500 IU/mL streptomycin, and 50 µg/mL gentamicin for 20 minutes
before being washed twice in low glucose DMEM supplemented
with 200 mM glutamine, 200 µg/mL penicillin, 200 IU/mL strepto-
mycin, and 50 µg/mL gentamicin (control medium).
One osteochondral explant, or approximately 60mg explanted
cartilage was placed into one well of a 24‐well plate, per treatment,
and equilibrated overnight in 1 mL of control medium at 37°C and 5%
CO2. This was considered day 0. Cartilage explants were weighed in a
sterile 1.5 mL tube with enough sterile filter paper at the bottom of
the tube to absorb media. Then, the tubes were centrifuged at full
speed in a benchtop centrifuge to remove excess media from the
explants. Explants were then placed into 1mL of control media in a
24‐well plate whilst tube +media/filter paper (no explant) were
weighed to determine explant weights. Explants were then placed
into fresh media with volumes adjusted so that the ratio was exactly
20 µL per mg explant for each well. The same exact volumes were
applied at subsequent media changes so that the ratio was main-
tained throughout the course of the experiment. Osteochondral ex-
plants were cultured in 1mL medium for 14 days. Explanted cartilage
was cultured in 20 µL media/mg explant for 7 days. Previous studies
from our laboratory have demonstrated chondrocyte viability and
metabolic activity in explants for culture periods of up to 28 days
with medium changes.
2.2 | Chondrocyte isolation and culture
Cartilage explants were also used for the isolation of primary equine
chondrocytes and collected as described above. Explants were diced and
then digested by sequential incubation with pronase (70U/mL for 1 hour
at 37°C; Roche) and collagenase (0.2% wt/vol, overnight at 37°C;
Gibco). Isolated passage 0 chondrocytes were seeded at high density
(105 000 cells/cm2—which was still a monolayer) and incubated in
high glucose (4.5 g/L) DMEM supplemented with 200mM glutamine,
200 µg/mL penicillin, 200 IU/mL streptomycin, 50 µg/mL gentamicin,
1mM sodium pyruvate, 10 µg/mL insulin, 5 µg/mL transferrin, and
6.7 ng/mL selenium (Gibco) (control medium), for 7 days.
2.2.1 | Experimental design
Cartilage explants and chondrocytes were subjected to the following
treatments; corresponding control medium in the presence or
absence of 0.1, 1.0 or 10 ng/mL TNF‐α (R&D Systems) and 0.1, 1.0, or
10 ng/mL IL‐1β (R&D Systems). Cartilage explants were also treated
with the anti‐inflammatory dexamethasone (at 100 μM). Os-
teochondral explants were incubated in control medium in the pre-
sence or absence of 10 ng/mL TNF‐α and 10 ng/mL IL‐1β. Media was
collected and replenished every 3.5 days from cartilage explants/
osteochondral grafts, and then combined to reflect the average re-
lease over the culture period (7 or 14 days). Protease inhibitor
cocktail (Halt, Thermo Fisher Scientific) was then added to collected
media. Monolayer chondrocytes were lysed, and protein extracted,
by 50mM Tris‐HCl (pH 6.8), 1% sodium dodecyl sulfate (wt/vol), 10%
glycerol (v/v) and protease inhibitor cocktail (Halt, Thermo Fisher
Scientific). Cell lysates were syringed with a 25 G needle to shear
nuclear DNA and centrifuged at 12 000g for 5 min to pellet cell
debris. Cell lysates, supernatants and spent media were stored at
−80°C prior to analysis. The “n” numbers refer to separate experi-
ments using explants/cells from individual animals (biological re-
plicates) in all cases.
2.3 | Western blotting
Cell lysate total protein was determined by using the Pierce bicincho-
ninic acid assay (Thermo Fisher Scientific), following the instructions of
the manufacturer. Media and cell lysate samples were subjected to
western blotting under reducing conditions. Explant media loading vo-
lumes were normalized to explant wet weight. Cell media and cell lysate
loading volumes were normalized to total cell protein. Generated by
pooling samples, positive control standards (STD) were used to nor-
malize between blots. Collagen type II standard (TII STD) was generated
by extraction of cartilage explants in 4M guanidine hydrochloride and
the insoluble pellet reconstituted in 0.5M acetic acid, and further diluted
with 50mM Tris‐acetate (pH 7.4). Samples and standards were loaded
onto 4% to 12% Tris‐glycine or 10% Bis‐Tris acrylamide gels (NuPAGE,
Invitrogen), then transferred onto 0.45 µm nitrocellulose membrane.
Membranes were blocked with 5% (w/v) bovine serum albumin (BSA) in
Tris‐buffered saline 0.1% Tween‐20 (vol/vol) (TBS‐T), or Odyssey
blocking buffer (Licor), for 1 hour at room temperature and then in-
cubated overnight at 4°C with the following primary antibodies diluted
in 5% BSA/TBS‐T or Odyssey blocking buffer with 0.2% Tween‐20; anti‐
CLU (Aviva Systems Biology ARP61142_P050), anti‐COMP (Abcam
ab128893), anti‐MMP‐3 (Aviva Systems Biology ARP42042_P050), anti‐
MMP‐13 (Aviva Systems Biology ARP56350_P050), anti‐collagen type II
(DSHB II‐II6B3), rabbit normal immunoglobulin G (IgG) control (12‐370;
Sigma‐Aldrich) or mouse normal IgG control (12‐371; Sigma‐Aldrich).
Bound primary antibodies were detected with goat anti‐rabbit or goat
anti‐mouse antibodies conjugated with alkaline phosphatase (Cambridge
Bioscience), IRDye 680RD or IRDye 800CW (LI‐COR Biosciences).
Positive bands were imaged using the LI‐COR Odyssey FC imaging
system (LI‐COR Biosciences) or by incubation in alkaline phosphatase
NBT/BICP buffer (Promega), and then quantified by densitometry ana-
lysis (Image J, NIH). Blots were imaged using the LI‐COR Odyssey FC
imaging system and quantification of detected bands was performed
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using the Image Studio software. Positive cell lysate bands were nor-
malized to total protein post transfer, detected by REVERT Total Protein
Stain (LI‐COR Biosciences). For explants, equal volumes of media were
loaded onto the gel since the experimental media volumes were already
normalized to explant weight. Cell media volumes loaded onto the gel
were normalized to total cell protein. REVERT was not used to correct
for explant media protein or cell media protein since we expected media
protein levels to change with cytokine treatment, due to increased re-
lease of matrix proteins; therefore, using REVERT to normalize densi-
tometry values would have negated any cytokine effects.
2.4 | Dimethylmethylene blue assay
sGAG content was determined by using the dimethylmethylene blue
(DMMB) colorimetric assay as previously described26 and chon-
droitin sulfate C, from shark cartilage, was used as a standard. Ab-
sorbance readings were taken at a wavelength of 525 nm on a Tecan
SPARK 10M plate reader.
2.5 | Real‐time quantitative polymerase chain
reaction
Cartilage explants were homogenized in TRI reagent using a dis-
membrator (Braun Biotech). RNA was isolated from explant homo-
genate and chondrocyte lysate by using the Qiagen RNeasy RNA
isolation kit and following the manufacturer's instructions. First
strand cDNA was then synthesized using SuperScript III reverse
transcriptase (Thermo Fisher Scientific), and real‐time polymerase
chain reaction (RT‐PCR) conducted using the Techne Prime Pro
thermal cycler with GoTaq qPCR Master Mix (Promega). Quantita-
tive RT‐PCR (RT‐qPCR) reactions were carried out in 10 μL volumes
containing 3.5 mM MgCl2, 200 μM dNTPs, 0.3 μM of sense and an-
tisense primers, 0.025 U/μL GoTaq polymerase enzyme and 1:66,000
SYBR Green‐1 (Thermo Fisher Scientific). CLU (NM_001081944)
Forward: CTA‐CTT‐CTG‐GAT‐CAA‐CGG‐TGA‐CC and Reverse:
CGG‐GTG‐AAG‐AAT‐CTG‐TCC‐T primers produced a 144 base pair
(bp) product. Clusterin gene expression was normalized to the
housekeeping gene ribosomal protein S18 (RPS18, XM_001497064)
using Forward: CAC‐AGG‐AGG‐CCT‐ACA‐CGC‐CG and Reverse:
AGG‐CTA‐TCT‐TCC‐GCC‐GCC‐CA primers (119 bp product).
2.6 | Statistics
Statistical tests were performed using the R statistical package
(CRAN). Data sets were checked for Gaussian distribution using
Shapiro‐Wilks tests and equal variance using Bartlett k2 tests; log
transformations were conducted to correct normality or unequal
variance if required. Tests for statistical significance were performed
using Student's paired t test and One‐way analysis of variance with
Tukey's HSD pair‐wise comparisons. Effect size was calculated using
Cohen's d test (with effect sizes classified as small (d ≥ 0.2), medium
(d ≥ 0.5), large (d ≥ 0.8) and very large (d ≥ 1.3).27 Mean values are
reported as ± standard error of the mean.
3 | RESULTS
3.1 | sGAG release from cartilage explants is
elevated by cytokine stimulation
To validate our in vitro model of cartilage degradation, we first
looked at the sGAG content of the explant secretome using DMMB
analysis. sGAG release was increased three‐fold following stimulation
with 10 ng/mL IL‐1β and TNF‐α compared with the control with a
very large effect size (fold change increase: FC = 2.98; P = .0058,
d = 2.3561; Figure 1A). Levels of the cartilage degradation marker
cartilage oligomeric matrix protein (COMP) in the explant secretome
were increased two‐fold with 10 ng/mL IL‐1β and TNF‐α stimulation
versus the control (FC = 1.94, P = .0218, d = 1.7963; Figure 1B), as
revealed by western blot analysis, demonstrating the catabolic effect
of cytokine treatment in this model. Uncropped blot images for
COMP are shown in Figure S1.
3.2 | Clusterin release from cartilage explants is
attenuated by cytokine stimulation
Mature sCLU is secreted as a heterodimeric protein with an apparent
molecular weight (MW) of 75 to 80 kDa. Under reducing conditions,
extracellular sCLU appears as α‐ and β‐chains of 34 to 36 kDa and 37 to
9 kDa, respectively.7 The α‐ and β‐bands usually appear as a smear,
rather than sharp bands, due to varying degrees of glycosylation.8 In-
tracellular forms of clusterin include the 60 kDa precursor secretory
clusterin (psCLU), the alternatively spliced 49 kDa precursor nuclear
CLU (pnCLU), and its 55 kDa post‐translationally modified nCLU.6,8
Western blot analysis of the articular cartilage explant secre-
tome in reducing conditions identified the glycosylated α‐ and
β‐chains of extracellular secreted sCLU between 34 and 39 kDa
(Figure 1C). Cartilage explants stimulated for 7 days with 10 ng/mL
IL‐1β and TNF‐α showed a 9‐fold reduction in sCLU release com-
pared with control (FC = –8.69; P = .00603, d = 1.2455). Uncropped
blot images for CLU are shown in Figure S1.
3.3 | Clusterin release from osteochondral explants
is attenuated by cytokine stimulation
sGAG release from osteochondral explants was also increased three‐
fold following stimulation with 10 ng/mL IL‐1β and TNF‐α compared
with the control, with a very large effect size (FC = 3.01; P = .002;
d= 5.8973; Figure 2A), indicating a similar response to cartilage ex-
plants. Western blot analysis showed that sCLU expression was
downregulated 363.9‐fold in the osteochondral biopsy secretome
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following 14 days of stimulation with 10 ng/mL IL‐1β and TNF‐α com-
pared with the control (P = .0011; d = 3.3291; Figure 2B). As observed in
the cartilage explant secretome, the glycosylated α‐ and β‐chains of
secreted sCLU were identified in the control osteochondral secretome
between 34 and 39 kDa. Uncropped blot images are shown in Figure S2.
3.4 | Clusterin release from cartilage explants is
reduced by physiologically relevant levels of cytokines
Levels of IL‐1β and TNF‐α found in the synovial fluid of patients
with OA are in the region of 0.1 ng/mL.28,29 We therefore aimed
to determine whether a lower concentration of IL‐1β and TNF‐α
had any effect on clusterin release in this model. sGAG release
into the explant secretome was gradually increased by 0.1, 1.0,
and 10 ng/mL IL‐1β and TNF‐α treatment compared with the
control (fold change increases: FC = 2.28, FC = 3.55, FC = 3.67;
P = .0283, P = .0067, P = .0044; and d = 1.4534, d = 1.746,
d = 1.8914, respectively; Figure 3A). In contrast, clusterin release
was significantly reduced following 0.1, 1.0, and 10 ng/mL IL‐1β
and TNF‐α treatment versus the control explants (FC decreases:
FC = –1.32, FC = –2.62, FC = –6.3; P = .0027, P = .0158, P < .0001;
and d = 1.1179, d = 2.0148, d = 5.9987, respectively). Uncropped
blot images are shown in Figure S3.
F IGURE 1 Release of sulfated
glycosaminoglycans (sGAG), cartilage
oligomeric matrix protein (COMP), and
secreted isoform of clusterin (sCLU) into the
secretome of articular cartilage explants,
following stimulation with 10 ng/mL tumor
necrosis factor α (TNF‐α) and 10 ng/mL
interleukin‐1β (IL‐1β) for 7 days. A, sGAG
quantified by dimethylmethylene blue
(DMMB) analysis. B, COMP; C, sCLU, and
rabbit immunoglobulin G (rIgG) controls,
detected by western blotting and quantified
by densitometry. Data shown are
mean ± SEM, n = 5. * and ** indicate significant
differences (P < .05 and P < .01, respectively)
as determined by Student's t test versus the
control (CTR) [Color figure can be viewed at
wileyonlinelibrary.com]
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3.5 | Clusterin release and gene expression in
cartilage explants is unaffected by MMP inhibition
To determine whether the loss of clusterin release upon proin-
flammatory cytokine stimulation was due to increased proteolytic
activity in the cartilage explant, and/or degradation of secreted
clusterin by matrix proteases, explants were treated with 10 ng/mL
TNF‐α, IL‐1β, and 100 μM dexamethasone in combination. Dex-
amethasone is an anti‐inflammatory steroidal drug known to reduce
MMP activity in cartilage.25 Release of clusterin from cartilage ex-
plants, and cartilage explant clusterin gene expression as detected by
RT‐qPCR, were both significantly attenuated by treatment with IL‐1β
and TNF‐α with very large effect sizes (FC reduction: FC = –109.61,
P = .0009, d = 4.8357; and FC = –596.57, P = .0002, d = 3.0197 vs the
control, respectively; Figure 4A,B), and the same effect was observed
when IL‐1β and TNF‐α were applied in combination with dex-
amethasone (FC reduction: FC = –79.44, P = .0009, d = 4.4183 and
FC = –204.65, P = .0005, d = 3.01 vs the control, respectively). In
contrast, whilst IL‐1β and TNF‐α significantly increased MMP13 and
MMP3 release into the explant secretome (FC = 10.73 increase,
P = .0004, d = 6.9966 and FC = 4.24 increase, P = .002, d = 4.8831
vs the control, respectively; Figure 4C,D), co‐application of dex-
amethasone with the cytokines abolished the increased levels of both
metalloproteinases in this explant model (FC = –9.61 reduction,
P = .021, d = 5.59 and FC = –1.95 reduction, P = .041, d = 3.37 vs
proinflammatory cytokine treatment, respectively; Figure 4C,D).
These data indicate that loss of secreted clusterin is unlikely due to
enhanced matrix protease activity since inhibition of MMP‐3 and
MMP‐13 by dexamethasone does not rescue cytokine‐induced re-
duction of either clusterin release or clusterin gene expression. Un-
cropped blot images are shown in Figure S4.
3.6 | Clusterin secretion from chondrocytes is
reduced by cytokine stimulation
Next, we looked at clusterin release in primary (unpassaged equine)
articular chondrocytes. Cells were cultured for 7 days in serum‐free
medium at high density. Secretion of sGAG and collagen type II was
maintained in the control cells for the duration of the experiment,
confirming the chondrocyte phenotype, as revealed by DMMB assay
and western blot analysis of the chondrocyte secretome, respectively
(Figure 5A,B). The α‐ and β‐chains of sCLU were present in the
chondrocyte secretome, and sCLU secretion was down‐regulated by
almost four‐fold with 10 ng/mL IL‐1β and TNF‐α stimulation, com-
pared with the control (FC = –3.79 reduction, P = .0138, d = 1.62), as
revealed by western blot analyses (Figure 5C). Treatment with dif-
ferent concentrations (0.1, 1, and 10mg/mL) of the cytokines re-
sulted in a dose‐dependent trend of reduced sGAG secretion
(Figure 5D). A gradually attenuated release of sCLU (Figure 5E) was
detected on western blots performed on the secretome following
stimulation with different concentrations of the proinflammatory
cytokines, similar to what has been observed with cartilage explants.
Uncropped blot images are shown in Figure S5.
3.7 | The sCLU isoform, but not the nCLU isoform,
could be detected intracellularly
Western blotting performed on total lysates of primary unpassaged
chondrocytes cultured for 7 days in serum‐free medium at high
density revealed the presence of intracellular clusterin (Figure 6A).
Uncropped blot images are shown in Figure S6. The MW of the band
corresponding to clusterin was confirmed at 41.1 kDa (±0.2),
F IGURE 2 Release of sGAG and sCLU into the secretome of osteochondral explants, following stimulation with 10 ng/mL TNF‐α and
10 ng/mL IL‐1β for 14 days. A, sGAG quantified by DMMB analysis. B, sCLU, detected by western blotting and quantified by densitometry. Data
shown are mean ± SEM, n = 5. * and ** indicate significant differences (P < .05 and P < .01, respectively) as determined by Student's t test versus
the CTR. CTR, control; DMMB, dimethylmethylene blue; IL‐1β, interleukin‐1β; sCLU, secreted isoform of clusterin; sGAG, sulfated
glycosaminoglycans; TNF‐α, tumor necrosis factor α
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indicating the presence of the intracellular CLU isoform, whilst no
positive bands were detected at 49 kDa or 55 kDa (see Figure S7),
which correspond to the predicted MWs of nCLU. It should be noted
that the anti‐clusterin primary antibody employed in this study
recognizes an epitope in a sequence which spans both exons 6 and
7 (NM_001831.4). sCLU and nCLU both share exons 6 and 7 and
differ only in the presence or absence of exons 1 and 2.7 Treatment
with the proinflammatory cytokines IL‐1β and TNF‐α at 10 ng/mL
significantly reduced the levels of the intracellular CLU isoform
(FC = –1.45 reduction, P = .0173, d = 1.2402), compared with the
control (Figure 6B).
3.8 | Clusterin gene expression in chondrocyte
cultures is decreased by cytokine stimulation
Clusterin gene expression was investigated using RT‐qPCR ana-
lysis of primary equine articular chondrocytes cultured in a
monolayer. Clusterin gene expression in chondrocyte cultures was
unaffected following 3 days of stimulation with 10 ng/mL IL‐1β and
TNF‐α; however, a 1.85‐fold decrease was evident 7 days post
stimulation compared with the control (P = .005, d = 8.6747), as
shown in Figure 6C.
4 | DISCUSSION
The aim of this study was to validate sCLU, a protein previously
implicated in OA pathophysiology, as a candidate biomarker of the
early degenerative changes induced by proinflammatory cytokines
using three in vitro culture model systems. The ultimate aim of this
study was to determine if sCLU may be proposed as a potential
investigative biomarker of early OA. Clusterin was identified as a
putative biomarker candidate by our previous proteomic study, using
an in vitro model of cartilage degradation,4,16 and proteomic and
transcriptome studies carried out by other groups, which analyzed
serum, plasma, synovial fluid and articular cartilage.13‐15,17,18,20‐23
Increases and decreases in clusterin levels have been reported with
disease, and these contradictory findings are perhaps due to the
existence of two isoforms of clusterin, and varying disease stage of
donor tissue. The difference is critical due to the opposing roles of
the two isoforms, and the relevance of isoform function in OA pa-
thology. By considering only sCLU, and by using a targeted approach
in a controlled in vitro model, we validated this candidate marker and
further elucidated its role in three in vitro culture model systems
frequently used to study early degenerative changes in articular
cartilage stimulated in response to pathophysiologically relevant
concentrations of proinflammatory cytokines implicated in low‐grade
inflammation in OA.
We used an equine articular cartilage explant model to monitor
sCLU release in response to the proinflammatory cytokines IL‐1β and
TNF‐α. In order to maintain consistency with previous work from our
laboratory,4,16 the proinflammatory cytokines were applied at the
pathophysiologically relevant concentration of 10 ng/mL to evaluate
early responses to cytokine‐stimulation in articular cartilage. How-
ever, given that the levels of IL‐1β and TNF‐α found in the synovial
fluid of patients with OA are in the realm of 0.1 ng/mL,28,29 we also
aimed at determining whether lower concentrations of IL‐1β and
TNF‐α had any effect on sCLU release in this model of cartilage
degradation. Incorporation of the osteochondral model in our
workflow meant that the influence of crosstalk, at the bone–cartilage
interface, on sCLU release could be ascertained.30 Analysis of the
secretome of primary chondrocytes removed the complication of
pre‐existing sCLU present in the cartilage matrix, enabling quantifi-
cation of only newly secreted sCLU.
F IGURE 3 Release of sGAG and sCLU into the secretome of
cartilage explants, following stimulation for 7 days with 0.1, 1, or
10 ng/mL TNF‐α and 0.1, 1, or 10 ng/mL IL‐1β. A, sGAG quantified by
DMMB analysis. B, sCLU, detected by western blotting and quantified by
densitometry. Data shown are mean± SEM, n=3. *, **, and *** indicate
significant difference (P< .05, P< .01, and P< .001, respectively) as
determined by hypothetical mean t test versus the CTR. CTR, control;
DMMB, dimethylmethylene blue; IL‐1β, interleukin‐1β; sCLU, secreted
isoform of clusterin; sGAG, sulfated glycosaminoglycans; TNF‐α, tumor
necrosis factor α [Color figure can be viewed at wileyonlinelibrary.com]
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IL‐1β and TNF‐α produced by the synovial membrane are key
contributors to the catabolic signaling and low‐grade inflammation
implicated in the development of early OA.31 These proinflammatory
cytokines suppress anabolic pathways whilst stimulating catabolic
enzymes, namely MMPs and aggrecanases.32,33 Increased levels of
MMPs results in intensified proteolysis, and the progressive loss of
the ECM.34 Proinflammatory cytokine induction of aggrecanases
leads to the loss of the large aggregating proteoglycan aggrecan, and
associated release of sGAG attachments.35,36 COMP mediates
chondrocyte attachment to the ECM,37 organizes ECM assembly, and
is an established marker of OA due to its correlation with disease
severity and presence in synovial fluid, serum and urine.38‐40
To demonstrate the validity and biological relevance of the
culture models of OA used in this study, we quantified MMP‐3,
MMP‐13, COMP, and sGAG released into the secretome of the
cartilage explant and osteochondral biopsy systems. Levels of
MMP‐3 and MMP‐13 were elevated in the cartilage explant model
following treatment with IL‐1β and TNF‐α. COMP levels also in-
creased in the cartilage explant secretome following proin-
flammatory cytokine treatment. The sGAG content of cartilage
explants was reduced with IL‐1β and TNF‐α stimulation confirming
early‐stage cartilage degradation in this model. sGAG release into
the secretome was elevated with proinflammatory cytokine sti-
mulation, in both cartilage explant and osteochondral biopsy
models to a similar extent, suggesting that aggrecanase‐driven
cartilage degradation was similarly induced in both models, high-
lighting the relevance of both models for identifying molecular
markers that reflect early catabolic changes. The addition of the
anti‐inflammatory compound dexamethasone reduced proin-
flammatory cytokine‐induced levels of MMP‐3 and 13 in the car-
tilage explant model. These observed changes are in line with our
previous work.4,16
F IGURE 4 Clusterin (CLU) expression in cartilage explants, and release of sCLU and matrix metalloproteinase (MMP) into the secretome of
cartilage explants, following stimulation for 7 days with 10 ng/mL TNF‐α and 10 ng/mL IL‐1β ± 10 μm dexamethasone (DEX). A, sCLU detected
by western blotting and quantified by densitometry. B, CLU gene expression quantified by real‐time quantitative real‐time‐polymerase chain
reaction (RT‐qPCR) analysis and normalized to ribosomal protein S18 (RPS18). C, MMP‐13, and (D) MMP‐3 detected by western blotting and
quantified by densitometry. Data shown are mean ± SEM, n = 3. *** indicates significant difference (P < .001) as determined by one‐way analysis
of variance (ANOVA) versus the CTR. #, ##, and ### indicate significant difference (P < .05, P < .01, and P < .001, respectively) as determined by
one‐way ANOVA versus TNF‐α + IL‐1β. CTR, control; IL‐1β, interleukin‐1β; sCLU, secreted isoform of clusterin; TNF‐α, tumor necrosis factor α
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To quantify the newly secreted sCLU without measuring pre‐
existing sCLU present in the cartilage matrix, we employed mono-
layer cultures of freshly isolated articular chondrocytes. sGAG
release into the spent culture medium was higher in the control
group, demonstrating the relevant biological activity associated
with the chondrocyte phenotype in vitro. Stimulation with the
proinflammatory cytokines IL‐1β and TNF‐α caused a decrease in
sGAG content of the secretome, consistent with previous studies
which also showed suppression of proteoglycan synthesis by cyto-
kines.41 Levels of both MMP‐3 and MMP‐13 were elevated with
proinflammatory cytokine treatment in the secretome of the chon-
drocyte monolayer model. This observation confirms the concordant
F IGURE 5 Release of sGAG, collagen type II, and CLU into the secretome of un‐passaged primary articular chondrocytes, following stimulation
for 3 or 7 days with TNF‐α and IL‐1β. A, Release of sGAG following stimulation for 3 or 7 days with 10 ng/mL TNF‐α and 10 ng/mL IL‐1β, quantified
by DMMB analysis. B, Release of collagen type II (TII) following stimulation for 3 or 7 days with 10 ng/mL TNF‐α and 10 ng/mL IL‐1β, detected by
western blotting and quantified by densitometry. Data shown are mean ± SEM, n = 6. # and ## indicate significant difference (P < .05 and P < .01,
respectively), as determined by one‐way ANOVA versus the CTR on day 3 or 7, respectively). C, Release of the secreted sCLU into the secretome,
following stimulation for 7 days with 10 ng/mL TNF‐α and 10 ng/mL IL‐1β, detected by western blotting and quantified by densitometry. Data shown
are mean ± SEM, n = 6. * indicates significant difference (P < .05) as determined by Student's t test versus the CTR. D, E, Release of sGAG and CLU
into the secretome of monolayer chondrocytes, following stimulation for 7 days with 0.1, 1, or 10 ng/mL TNF‐α and 0.1, 1, or 10 ng/mL IL‐1β. sGAG
release was quantified by DMMB analysis; sCLU release was detected by western blotting and quantified by densitometry. Data shown are
mean ± SEM, n = 2. ANOVA, analysis of variance; CLU, clusterin; CTR, control; DMMB, dimethylmethylene blue; IL‐1β, interleukin‐1β; sCLU, secreted
isoform of clusterin; sGAG, sulfated glycosaminoglycans; TNF‐α, tumor necrosis factor α [Color figure can be viewed at wileyonlinelibrary.com]
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responses of all three culture models to proinflammatory cytokines.
Furthermore, all three culture models exhibited a marked reduction
in sCLU release with IL‐1β and TNF‐α stimulation. We also showed
that in monolayer chondrocytes and cartilage explants, clusterin gene
expression was downregulated following 7‐days of stimulation with
IL‐1β and TNF‐α, which is in line with our previous data showing a
reduction in CLU precursor release.16 The addition of dex-
amethasone did not affect sCLU release from cartilage explants,
which suggests that the loss of clusterin is MMP‐3 and 13 in-
dependent. In addition, sCLU secretion was just as marked in the
osteochondral model despite reduced MMP release, suggesting
bone‐cartilage cross‐talk, and that MMP levels have little influence
on the fate of sCLU. Taken together, it is likely that the loss in sCLU
secretion from cartilage is due to an interruption at transcriptional
level, rather than degradation of extracellular sCLU. It has been re-
ported that transforming growth factor beta (TGF‐β) regulates the
expression of CLU through the transcription factor c‐Fos.42 c‐Fos
represses CLU expression of in the absence of TGF‐β, and conversely
TGF‐β inhibits c‐Fos, resulting in increased CLU expression.42 IL‐1β
and TNF‐α have both been shown to exert a suppressive effect on
TGF‐β signaling 43 possibly accounting for the loss of sCLU observed
in our study.
Clusterin is a protein that is constitutively produced and se-
creted by mammalian cells. It can function as a cytoprotective cha-
perone, aiding protein refolding, preventing aggregation under stress
conditions, enhancing cell proliferation and cell‐viability.7 In this
study, we show that the proinflammatory cytokines IL‐1β and TNF‐α
interrupt the expression and secretion of sCLU, and may therefore
interfere with the protection it offers to cells. The balance between
IL‐1β, TNF‐α and TGF‐β signaling pathways is crucial for maintenance
of articular cartilage homeostasis and its disruption likely plays a key
role in the pathogenesis of OA. We propose that this may be, in part,
due to the loss of a variety of cytoprotective factors, such as the
secreted isoform of clusterin.
Both increases and decreases in clusterin levels have been re-
ported in cartilage explants, synovium, synovial fluid and plasma of
patients with OA, depending on the experimental design, and varying
disease stage of donor tissue.13‐15,17,19,20,23 Clusterin is increased at
the transcriptional level in early OA cartilage, and decreased in ad-
vanced OA.17 Although detectable, clusterin is significantly reduced
in OA samples compared with healthy.18,21 Clusterin is increased in
plasma, and synovial fluid, from patients with OA, and peptide levels
of clusterin have been suggested to be as predictive of OA pro-
gression as age23; and may represent activation of a compensatory,
but ultimately ineffective, protective pathway.15
The in vitro explant model stimulated with proinflammatory cyto-
kines mimics the early events that occur during the onset of disease, the
mechanisms of which may precede events observed in early clinical OA
samples derived from bio‐banks. Our group has previously reported
decreased release of clusterin from cartilage explants stimulated with
IL‐1β, using high‐throughput mass spectrometry, which not only sup-
ports the findings in our current study, but also allowed us to develop a
new hypothesis implicating sCLU in early catabolic changes.4,16 Another
published study also showed decreased clusterin release with IL‐1β
treatment in mouse femoral head cartilage.44 Conversely, increased
clusterin release from bovine articular cartilage has been observed
following IL‐1β and TNF‐α stimulation.45
F IGURE 6 Clusterin protein and messenger RNA (mRNA)
expression in un‐passaged primary articular chondrocytes, following
stimulation for 7 days with 10 ng/mL TNF‐α and 10 ng/mL IL‐1β. A, B,
Secreted sCLU, and rabbit IgG (rIgG) control, detected by western
blotting and quantified by densitometry; normalized to total protein
loaded. Data shown are mean ± SEM, n = 6. * indicates significant
difference (P < .05) as determined by Student's t test versus the CTR.
C, CLU mRNA quantified by real‐time RT‐qPCR analysis, after being
normalized to ribosomal protein S18 (RPS18). Data shown are
mean ± SEM, n = 3. ## indicates significant difference (P < 0.01) as
determined by one‐way ANOVA versus the control (CTR) on day 7).
CLU, clusterin; CTR, control; IL‐1β, interleukin‐1β; rIgG, rabbit
immunoglobulin G; RT‐qPCR, quantitative real‐time transcription‐
polymerase chain reraction; sCLU, secreted isoform of clusterin;
sGAG, sulfated glycosaminoglycans; TNF‐α, tumor necrosis factor α
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It is important to emphasize the novelty of the observations de-
scribed in this paper. Only in our proteomic study has the issue of
clusterin isoforms been identified.16 Previous studies have not explored
or discussed this issue and therefore there is a need for further mole-
cular studies that focus of clusterin isoforms. It is possible that the
differences between the biological actions of sCLU and nCLU explain
the current contradictory picture, and increases in nCLU with simulta-
neous decreases in sCLU may account for the variability in clusterin
levels reported in the literature. The nuclear isoform has an antithetical
function to sCLU, and acts as a pro‐death signal, inhibiting cell growth
and survival.8,46‐48 Cytoplasmic pnCLU is posttranslationally modified in
response to cell damage and cytotoxic events, and nCLU translocates to
the nucleus where it induces apoptosis.6,8 Chondrocyte apoptosis is a
key process in OA and is associated with disease progression, with late‐
stage exhibiting higher levels of cell death.49,50 Elevated levels of clus-
terin in late stage disease15,17,19,20,23 could be due to the release of
intracellular nCLU following programmed cell death, whereas loss of the
protective sCLU could reflect disease onset. It is essential that further
future studies are carefully designed and carried out to distinguish
between the actions of these two CLU isoforms.
5 | CONCLUSION
This study has, for the first time, identified specifically the secreted
isoform of clusterin, sCLU, in three in vitro model systems that are
used to model the low‐grade inflammatory micro‐environment in
early OA. We concede that our in vitro models do not incorporate
the mechanical signaling that is thought to be involved in early de-
generative changes in OA but all three models consistently showed a
loss of sCLU secretion with proinflammatory cytokine stimulation.
Loss of cytoprotective sCLU in early OA could lead to increased
cellular stress, which may promote further catabolic activity and
contribute to OA progression. We propose that early OA biomarkers
will be extremely challenging to identify if we resort only to pro-
spective clinical studies with bio‐banked samples. Ex vivo model
systems have a valuable place in biological discovery in the context of
OA biomarkers and three‐dimernsional biomimetic culture models
can be used to identify candidate biomarkers for further considera-
tion as investigative biomarkers. Further studies are needed to de-
termine if the sCLU is a potential biomarker for the onset of OA.
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